Avalyn Raises $175 Million in Oversubscribed Series C Financing to Advance Inhaled Pulmonary Fibrosis Programs into Later Stage Clinical Studies - 9/27/2023
RiverVest’s latest Expert Insight explores the role of patient advocacy groups in therapeutic drug development for patients with rare diseases such as mitochondrial disease.
RiverVest led the Series A investment in Standard Bariatrics in 2018. The surgical device company was acquired by Teleflex, Inc. in 2022 for $170 million plus additional milestone payments.
(June 14, 2023) – In this article, Managing Director Niall O’Donnell, Ph.D. discusses the law that transformed orphan drug development and how one actor’s starring role in its passage spurred 40 years of prolific, life-saving innovation.
ST. LOUIS (September 7, 2022) – Good Therapeutics – a RiverVest Venture Fund IV portfolio company – has entered into a definitive merger agreement to be acquired by…
RiverVest strives to improve the lives of patients, support entrepreneurs, and earn the trust of investors through science, strategy, and innovation.Contact us at info@rivervest.com
Transparency in Coverage Rule: To access the machine-readable files created and published by United Healthcare, please click here.